Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m Professional…
Lucid Diligence Brief: AAVantgarde Bio $141M Series B
Lucid Diligence Brief: AAVantgarde Bio $141M Series B Professional audiences…
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A Professional…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
BioPharma Corporate Venture Capital Investment Trends (2020 edition)
We recently analyzed the portfolios and activities of 22 BioPharma CVCs; you…